Virus-like particle vaccines and adjuvants: the HPV paradigm.
Complex antigen structures currently represent the most-studied approach for prophylactic as well as therapeutic vaccines. Different types of complex vaccines, including virus-like particles and virosomes, have been developed depending on the nature of the viral pathogen they are trying to replicate (enveloped vs naked) or the modality to express antigenic epitopes (i.e., the binding of envelope protein on liposomic structures). The complex structure of these vaccines provides them with some adjuvanted properties, not uniformly present for all virus-like particle types. The further inclusion of specific adjuvants in vaccine preparations can modify the presentation modality of such particles to the immune system with a specific Th1 versus Th2 polarization efficacy. A paradigm of the relevance of these new adjuvants are the immunological results obtained with the inclusion of monophosphoryl lipid A adjuvant in the formulation of L1-based human papillomavirus-naked virus-like particles to reduce a Th1 cellular immunity impairment, peculiar for alum-derived adjuvants, along with the induction of highly enhanced humoral and memory B-cellular immunity.
Buonaguro
Franco Maria
FM
Molecular Biology and Viral Oncology, Department of Experimental Oncology, Istituto Nazionale Tumori Fond Pascale, Via Mariano Semmola 142, 80131 Napoli, Italy. irccsvir@unina.it
Tornesello
Maria Lina
ML
Buonaguro
Luigi
L
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D052685:Alphapapillomavirus / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D015195:Drug Design; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D056724:Immunity, Humoral / Q000187:drug effects; D007156:Immunologic Memory / Q000187:drug effects; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000009:adverse effects / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects / Q000276:immunology / Q000821:virology; D019444:Vaccines, DNA / Q000276:immunology; D022721:Vaccines, Virosome / Q000276:immunology; D014771:Virion / Q000276:immunology*; D022701:Virosomes / Q000276:immunology
D000276:Adjuvants, Immunologic; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA; D022721:Vaccines, Virosome; D022701:Virosomes